DDX53 and neoplasm: To investigate whether sgZbtb7b enhances the anti-tumor efficacy of PD-L1 mAb, sgZbtb7b CT26 and LLC cells were inoculated into immunocompetent mice and treated with PD-L1 mAb or IgG isotype control (IgG2a) (Fig. 5E and Supplementary Fig. S16A).